PressApril 7, 2022 PharmaDrug Advances DMT-Analogue Program for Glaucoma with Production of Medical Device Designed to Provide Sustained Control of Elevated Intraocular Pressure
PressApril 5, 2022 Field Trip Health Ltd. Granted US Patent Covering Novel Psychedelic Molecule FT-104
PressMarch 31, 2022 Cybin Announces Initiation of Kernel Flow Feasibility Study Measuring Psychedelic Effects on the Brain
PressMarch 30, 2022 Albert Labs’ Files U.S. Provisional Patent Application for a Cultivation Process for the Production of Psilocybe Mycelia, as well as other Fungi Species
PressMarch 29, 2022 Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial
PressMarch 25, 2022 Biomind Labs to Commence Commercial Clinical Trial on Its Proprietary Mescaline Candidate BMND06
PressMarch 24, 2022 COMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK
PressMarch 22, 2022 Wesana Health Announces New Findings Indicating Psilocybin Potentiates Impact of an Anti-Depressant
PressMarch 21, 2022 Core One Labs to Investigate Soliciting Investment and Potential Takeover Opportunities
PressMarch 18, 2022 Optimi Health Begins Cultivation Of Natural Psilocybin For Use In Clinical Trials
PressMarch 17, 2022 Awakn Life Sciences Receives Regulatory to Begin Delivering Treatments in London Clinic
PressMarch 15, 2022 Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial
PressMarch 11, 2022 Albert Labs Closes $4.7m Private Placement; Begins Trading On The Canadian Securities Exchange
PressMarch 10, 2022 Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets
